Liu Hanzhi

Liu Hanzhi

This data is missing

Overview chart

, add related content, make data more complete, but also quickly upgrade, come on!

Liu Hanzhi, male, bachelor, researcher, master supervisor.

Name card

Surname and first name: Liu Hanzhi

Sex: Male

Position: Director of science and Education Department

Title: researcher, master supervisor

Academic history: Bachelor

Address: 288 Nanjing Road, Heping District, Tianjin

Postal Code: 300020

Educational experience

From September 1979 to August 1984, he studied at Bethune Medical University with a bachelor's degree

work experience

1984.8-1990.12 Institute of Hematology, Chinese Academy of Medical Sciences, experimental nuclear medicine, intern researcher

1990.12-1995.3 assistant researcher, experimental nuclear medicine, Institute of Hematology, Chinese Academy of Medical Sciences

1995.4-1999.7 associate researcher, research management, Institute of Hematology, Chinese Academy of Medical Sciences

1999.8-2005.8 associate researcher, administrative management, Institute of Hematology, Chinese Academy of Medical Sciences

September 2005 -- research management, researcher, Institute of Hematology, Chinese Academy of Medical Sciences

September 2009 - General Manager of Xiehe stem cell genetic engineering Co., Ltd

Undertaking scientific research projects in research

1. Study on the micro bifunctional antibody 1996-2000863-102-09-03-03

2. Studies on the properties and functions of intracellular M-CSF and its receptor, 1998-2000, National Natural Science Foundation of China, 39770371

3. Construction and experimental study of maf-j6-1 and its receptor fusion gene vaccine, 2000-2002, National Natural Science Foundation of China, 3980014

4. Preclinical study of chimeric antibody (cd20f (AB) 2 fragment and its isotope labeling, 2001-20038632001aa215341

5. Development of bifunctional genetic engineering antibody against tumor angiogenesis, Tianjin basic key, 2005-2007, 05yfjzjc01200

Representative works

1.Invivothrombolyticpropertiesofurokinasedirectedbybispecificmonoclonalantibodyforurokinaseandforhumanfibrin，《thrombosisandhaemostasis》P504，1997

2.Modulatingmultidrugresistancethroughinhibitingofproteinkinasecactivitybyphenothiazines，《ChineseScienceBulletin》43(14):1196,1998

3.StudiesofcytotoxicmechanismsofIL-2andLFN-alphaactivatedlymphocytesontumorcells，《Blood》92(10):60b,1998

4.ThekillingeffectofIL-2andIFN-2activatedleukemicbonemarrowonK562cells，《Blood》92(10):317b,1998

5.ReversibleexposureofhumanplateletfibrinogenreceptorsbyantiplatelettetraspaninmonoclonalantibodiesviainductionofaconformationalchangeinmembraneglycoproteinⅡb/Ⅲαcomplex，《Thrombosisresearch》95:245-253,1999

6.Activationofplateletintegrin2Ⅱb/β3inducedbytwomonoclonalantibodiesdirectedagainsthumanplatelettetraspanin，《Thrombhaemost》 suppl:357 ,1999

7.Studiesonthemechanismofinductionofplateletfibrinoqenreceptorsbyanti-platelettetraspaninmonoclonalantibodies，《Blood》94（10）：68b,1999

8.Internalizationandhalf-lifeofmembrane-boundmacrophagecolony-stimulatingfactor，《ChineseScienceBulletin》45（18）：1697，2000

9.Anti-humanplatelettetraspain(CD9)monoclonalantibodiesinduceplateletintegrinαⅡbβ3activationinaFCreceptor-independentfashion.《ChineseMedicalJournal》15(3)：145-149，2001

10.AutocrineandpossibleintracrineregulationofHL-60cellproliferationbymacrophagecolony-stimulatingfactor，《LeukemiaResearch》25:1107,2001

11.Efficacyofanti-CD20chimericFab’fragmentonproliferationofBlymphomacells.《ChineseScienceBulletin》46(14):1182,2001

12.EfficientinhibitionofhumanB-celllymphomaxenograftswithananti-CD20Xanti–CD3bispecificdiabody.《Cancerletters》177:29-39,2002

13.EfficientInhibitionofMulti-drugResistantHumanTumorswithaRecombinantBispecificAnti-P-glycoproteinxAnti-CD3Diabody，《Leukemia》18(3):513-520，2004

14. Study on the condition of labeling anti-cd20f (ab ') 2 by NBS method, Journal of radioimmunology 17 (1): 192004